PhD candidate Jenni Virta will defend her thesis on August 9th 2024

PhD Candidate Jenni Virta will defend her thesis on August 9th 2024

MSc Jenni Virta will defend her dissertation titeled

"POSITRON EMISSION TOMOGRAPHY IMAGING OF DISEASE ACTIVITY IN ATHEROSCLEROSIS"

at at the University of Turku on 09 August 2024 at 12.00 pm - 16.00 pm (TYKS T Hospital, Risto Lahesmaa auditorium, Hämeentie 11, 20520 Turku).

Opponent : Professor Sohvi Hörkkö  (University of Oulu)

Custos : Professor Antti Saraste (University of Turku)

Examination format : On site, Finnish.

The field of the dissertation is clinical physiology and nuclear medicine and conducted at Turku PET Centre, University of Turku, Finland.

The electronic book of her dissertation can be accessed via university's repository https://www.utupub.fi/handle/10024/178833

Summary of the dissertation:

Atherosclerosis is a progressive inflammatory disease in which fat and inflammatory cells, such as eating cells, accumulate on the walls of blood vessels. Atherosclerotic artery diseases, such as coronary artery disease, are the leading cause of death worldwide. Type 2 diabetes is an important risk factor for atherosclerosis, affecting an estimated more than 370 million people worldwide and increasing alarmingly among younger people. The eating cells of the artery wall play an important role in regulating the disease activity of atherosclerosis and can either prevent or promote the progression of the disease.

Positron emission tomography, or PET, is an imaging method that can be used to describe biological functions in living objects. PET imaging can be used in disease research, diagnostics and treatment monitoring. For the imaging of atherosclerosis, new specific markers are needed that target inflammation, more precisely, activated eating cells, which would make it possible to assess the disease activity of atherosclerosis.

The dissertation investigated the suitability of three new PET tracers 68Ga-NODAGA-exendin-4, (2S, 4R)-4-[18F]fluoroglutamine (18F-FGln) and 18F-AlF-NOTA-folate (18F-FOL) for imaging atherosclerosis disease activity. In addition, the effects of linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used as an antidiabetic drug, on atherosclerosis activity were investigated using PET imaging with the most commonly used 2-deoxy-2-[18F]fluoro-D-glucose (18F-FDG) marker. The studies were conducted using experimental models of atherosclerosis and type 2 diabetes.

The results showed that 68Ga-NODAGA-exendin-4, 18F-FGln and 18F-FOL enable PET imaging of atherosclerotic plaque-eating cells. Treatment with linagliptin did not have the desired effect on atherosclerosis activity or fatty liver, although it improved sugar tolerance and reduced liver inflammation. The study provides new information on the possibilities of PET imaging of atherosclerosis disease activity.

PhD candidate Max Miner will defend his thesis on August 29th 2023

Max Miner defends his dissertation entitled “Emerging Radiopharmacetuicals for PET-imaging Gliomas” at the University of Turku on 29 August 2023 at 12.00 pm (TYKS T Hospital, Risto Lahesmaa auditorium, Hämeentie 11, 20520 Turku).

The audience can participate in the defence by remote access: https://utu.zoom.us/j/62033783502

Opponent: Professor Klaus Kopka (Helmholtz-Zentrum Dresden-Rossendorf Research Centre, Germany)
Custos: Professor Anne Roivainen (University of Turku)

PhD candidate Riikka Viitanen will defend her thesis on February 19th 2021

Riikka will defend her thesis titled “Evaluation of 68Ga-labeled PET radiopharmaceuticals for imaging of avß3 integrin and vascular adhesion protein-1 in inflammation and cancer”. Her thesis can be found in the University of Turku Annales: http://urn.fi/URN:ISBN:978-951-29-8360-5.

The public event will be held Friday February 19th 2021 at 12 o’clock as an online defence. D.Med.Sc Johanna Huhtakangas (Kuopio University Hospital) will act as the opponent and professor Anne Roivainen as the custodian. The defence is in Finnish.

More info (Finnish): https://www.utu.fi/fi/ajankohtaista/tapahtumat/vaitos-kliininen-fysiologia-ja-isotooppilaaketiede-fm-riikka-viitanen

PhD student Mia Ståhle is defending her thesis on November 28th 2020

Mia will defend her thesis titled “Molecular imaging and immunotherapy in atherosclerotic cardiovascular disease”. Her thesis can be found in the University of Turku Annales: http://urn.fi/URN:ISBN:978-951-29-8258-5.

The public event will be held Saturday November 28th 2020 at 12 o’clock in the Risto Lahesmaa – lecture hall (TYSK T-Hospital, Hämeenkatu 11, Turku). Professor Risto Kerkelä (University of Oulu) will act as the opponent and professor Juhani Knuuti as the custodian. The defence is in Finnish.

The event can be observed online trough this link: https://utu.zoom.us/j/63740713455?pwd=elh5RG83V3RXbkZTUDNtNnVTcE4xZz09.

PhD student Petri Elo defends thesis on November 6th 2020

Petri will defend his thesis titled “Preclinical evaluation of novel radiopharmaceuticals for positron emission tomography imaging of animal models of multiple sclerosis”. His thesis can be found in the University of Turku Annales: http://urn.fi/URN:ISBN:978-951-29-8182-3.

The public event will be held Friday November 6th 2020 at 12 o’clock in the Johan Haartman – lecture hall (TYSK T-Hospital, Hämeenkatu 11, Turku). Professor Andrea Varrone (Karolinska instutet, Sweden) will act as the opponent and professor Anne Roivainen as the custodian.

You can follow the defence online at https://utu.zoom.us/j/64592782155?pwd=aDk0Wlovai9LVGY1WFhIV0FOSXBpdz09.

PhD candidate Maria Grönman defends her thesis October 9th 2020

Maria will defend her thesis titled “PET imaging of ischaemic myocardial injury and angiogenesis”. Her thesis can be found in the University of Turku Annales: http://urn.fi/URN:ISBN:978-951-29-8157-1.

The public event will be held Friday October 9th 2020 at 12 o’clock in the Risto Lahesmaa – lecture hall (TYSK T-Hospital, Hämeenkatu 11, Turku). Professor Tomi Laitinen (University of Eastern Finland) will act as the opponent and professor Antti Saraste as the custodian. The defence is in Finnish.

The event can be observed online trough this link: https://recorder.uc.2m-it.fi/streamit/lahesmaa.html.

PhD student Riikka Viitanen has received the Alavi-Mandell Award

A member of our group has received an award!

Riikka Viitanen, a PhD student at Turku PET Centre and Drug Research Doctoral Programme of University of Turku Graduate School, has been awarded the annual Alavi-Mandell Award from the Society of Nuclear Medicine and Molecular Imaging for her publication in the Journal of Nuclear Medicine. She is the first author of paper entitled with “68Ga-DOTA-E[c(RGDfK)]Positron Emission Tomography Imaging of SHARPIN-Regulated Integrin Activity in Mice”.

 

http://jnm.snmjournals.org/content/60/10/1380.long

Alavi-Mandell Award is given to individuals who were the first author of a paper published in the Journal of Nuclear Medicine that were trainees at the time the published work was carried out and made a major contribution to the completion of the work. The Alavi-Mandell Award aims to encourage the young scientists to pursue a career in academic and research in nuclear medicine.

Meeri Käkelä defends her PhD thesis February 29th 2020

Meeri will defend her thesis titled “Gallium-68 radiolabeling of biomolecules for positron emission tomography with special reference to imaging of inflammation and bone”.

The public event will be held Saturday February 29th 2020 at 12 o’clock in the Lauren 2 lecture hall (Medisiina D, Kiinamyllynkatu 10). Associate Professor (VU University Amsterdam) will act as the opponent and professor Anne Roivainen as the custodian. The dissertation is in English.

 

The first VAP-1 targeted PET tracer [68Ga]Ga-DOTA-Siglec-9 has finally entered in clinical trials at Turku PET Centre.

The first VAP-1 targeted PET tracer [68Ga]Ga-DOTA-Siglec-9 has finally entered in clinical trials. Sofar, two healthy volunteers have successfully been imaged at Turku PET Centre. (ClinicalTrials.gov Identifier: NCT03755245: Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis (SIGLEC))